Media coverage about Repros Therapeutics (NASDAQ:RPRX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repros Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.0743881619434 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the headlines that may have impacted Accern’s rankings:

Separately, S&P Equity Research cut their target price on shares of Repros Therapeutics from $0.49 to $0.39 in a research note on Monday, November 20th.

Shares of Repros Therapeutics (NASDAQ:RPRX) opened at $0.64 on Thursday. Repros Therapeutics has a one year low of $0.26 and a one year high of $1.55.

Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Monday, November 13th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.24. Repros Therapeutics had a negative net margin of 4,242.73% and a negative return on equity of 894.22%. The company had revenue of $0.30 million for the quarter.

TRADEMARK VIOLATION NOTICE: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://theolympiareport.com/2017/12/21/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-repros-therapeutics-rprx-share-price.html.

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Insider Buying and Selling by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.